ALK and non-small cell lung carcinoma: Similarly, cMET inhibitors cabozantinib and capmatinib completely suppressed CAF-mediated protection in experimental models of ALK+, EGFR mutant, and KRASG12C NSCLC (Fig. 1F, S2F–I).